Propionyl-L-carnitine in intermittent claudication: double-blind, placebo-controlled, dose titration, multicenter...

Area of Science:

• Cardiovascular Medicine
• Pharmacology
• Clinical Trials

Background:

• Propionyl-L-carnitine enhances carnitine content and energy metabolism in ischemic skeletal muscle.
• Preclinical studies suggest potential benefits for conditions involving impaired energy metabolism.

Purpose of the Study:

• To evaluate the efficacy and safety of propionyl-L-carnitine in treating intermittent claudication.
• To assess the dose-response relationship of propionyl-L-carnitine in this patient population.

Main Methods:

• A double-blind, placebo-controlled, multicenter trial involving 245 patients with intermittent claudication.
• Randomized assignment to propionyl-L-carnitine or placebo, with dose titration up to 3 g/day over 24 weeks.
• Efficacy assessed by maximal walking distance and onset of claudication on a treadmill.

Main Results:

• Propionyl-L-carnitine significantly improved maximal walking distance by 73% compared to 46% in the placebo group (p=0.03).
• While propionyl-L-carnitine showed a trend towards greater improvement in the distance to claudication onset, this was not statistically significant.
• No adverse effects were noted in biochemical, hematologic, or ECG tests; discontinuation events were infrequent and unrelated to the study drug.

Conclusions:

• Propionyl-L-carnitine, particularly at doses of 1-2 g/day, demonstrates efficacy in improving maximal walking distance for intermittent claudication.
• The treatment is well-tolerated with a favorable safety profile and minimal adverse effects.
• Further research may clarify the exact mechanism of therapeutic action.